ARTICLE | Clinical News
RTX resiniferatoxin: Expanded Phase II studies
July 12, 1999 7:00 AM UTC
Afferon Corp., Wayne, Penn. Product: RTX resiniferatoxin Business: Urological, Neurological Therapeutic category: Neurotransmission Target: Peripheral sensory neurons Description: Neuronal desensitizi...